Leqvio (Inclisiran) Cost in West Virginia 2026

What Is Inclisiran and Why Does Cost Matter in West Virginia?

Inclisiran (brand name Leqvio) is a small-interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 inside hepatocytes, reducing LDL-C by roughly 50% with only two injections per year after the initial loading period [1]. West Virginia consistently ranks among the top five states in the nation for cardiovascular mortality, with an age-adjusted heart disease death rate of 247.1 per 100 to 000 in 2021 according to the CDC [2]. That epidemiological backdrop makes affordable access to a potent LDL-lowering agent medically meaningful for a large share of WV residents.

The drug received FDA approval on December 22, 2021, for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering beyond maximally tolerated statins [3]. Despite strong clinical data, its list price creates a real barrier in a state where median household income sits well below the national average. Understanding the full cost picture, including insurance, Medicaid, manufacturer support, and compounded alternatives, is therefore not an abstract exercise for West Virginians; it is a clinical necessity.

Inclisiran works differently from the monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent). Those biologics block circulating PCSK9 protein. Inclisiran silences the messenger RNA that produces PCSK9 in the first place, which is why a single subcutaneous injection maintains LDL-C suppression for approximately six months [4].

How Much Does Leqvio Cost in West Virginia Without Insurance?

Without insurance, the cash price for Leqvio in West Virginia mirrors the national Novartis list price of approximately $540 per month, which translates to roughly $3,240 per biannual injection when annualized. The dosing schedule is: day 1, day 90, then every 180 days thereafter. Two injections per year means the annual medication cost at list price is approximately $6,480 before any discounts [3].

Retail pharmacy cash pricing in West Virginia follows the national average closely. GoodRx and similar pharmacy benefit managers may list slightly lower negotiated prices at chains such as Kroger, Walmart, and CVS locations in Charleston, Huntington, and Morgantown, but those negotiated rates typically reduce the price by only 5 to 10 percent off list, leaving the net cost well above $6,000 annually for an uninsured patient.

For context, the Institute for Clinical and Economic Review (ICER) concluded in its 2021 report that inclisiran's cost-effectiveness threshold at $100,000 per quality-adjusted life-year (QALY) would require a price of approximately $4,100 to $5,200 per year for high-risk ASCVD patients [5]. The current list price exceeds even the upper bound of that range, reinforcing why manufacturer and insurance pathways matter so much in lower-income states like West Virginia.

Does West Virginia Medicaid Cover Leqvio?

West Virginia Medicaid does not cover Leqvio as of 2026. The WV Bureau for Medical Services has not added inclisiran to its preferred drug list (PDL), and no prior authorization pathway has been established for it in the Medicaid fee-for-service program. Managed care organizations operating under WV Medicaid similarly exclude inclisiran from their formularies.

This gap is significant. Approximately 27% of West Virginia residents are enrolled in Medicaid [2], meaning a large segment of the population most burdened by cardiovascular disease has no state-funded access to the drug. The American College of Cardiology and American Heart Association 2022 guidelines on cholesterol management list PCSK9 inhibitors as a Class I recommendation for very-high-risk ASCVD patients with LDL-C <70 mg/dL on maximally tolerated statin therapy, but that guideline strength has not translated into WV Medicaid formulary access for inclisiran [6].

Patients on WV Medicaid who need aggressive LDL-C lowering should work with their prescriber to explore covered PCSK9 inhibitors. Evolocumab (Repatha) and alirocumab (Praluent) both appear on some WV Medicaid managed care formularies with prior authorization requirements, making them a de facto alternative pathway when inclisiran coverage is denied.

What Commercial Insurance Plans Cover Leqvio in West Virginia?

Commercial coverage for Leqvio in West Virginia follows national insurer formulary decisions more than any state-specific policy. Medicare Part B covers inclisiran as a physician-administered drug under the buy-and-bill model because the injection is given in a clinical setting, not self-administered at home [3]. Medicare beneficiaries in West Virginia with ASCVD or HeFH should ask their cardiologist or primary care provider whether inclisiran can be administered in-office and billed to Part B, which bypasses Part D formulary restrictions entirely.

For commercially insured patients, major carriers including Highmark West Virginia, Aetna, Cigna, and UnitedHealthcare have tiered inclisiran on specialty formularies. Most require prior authorization demonstrating that the patient has an established ASCVD diagnosis or confirmed HeFH, is already on maximally tolerated statin therapy, and has an LDL-C that remains above 70 mg/dL (or above 100 mg/dL for primary prevention in HeFH). Step-therapy requirements may mandate a trial of ezetimibe before inclisiran is approved.

The Novartis PCSK9Rx Access Program works alongside commercial insurance. For eligible commercially insured patients, Novartis states that out-of-pocket costs can be reduced to $0 per dose [7]. Patients must not be enrolled in any federal or state government insurance program, including Medicare or Medicaid, to use this card. Income verification may be required.

How Does the Novartis Leqvio Savings Card Work for West Virginia Patients?

The Novartis savings card for Leqvio reduces the patient's co-pay, co-insurance, or deductible contribution to $0 per dose for commercially insured patients who meet eligibility criteria [7]. The program covers the gap between what the insurer pays and what the patient would otherwise owe, up to a maximum annual benefit. Patients enroll through the Leqvio patient support program at the Novartis website or by calling the number on the FDA-approved labeling.

Enrollment steps for a West Virginia patient are the same as nationally. The prescriber submits a prior authorization to the commercial insurer, the insurer approves (or the prescriber appeals a denial), and the patient presents the savings card at the administering physician's office or specialty pharmacy. The card is not accepted at retail pharmacies because Leqvio is dispensed through specialty pharmacy channels, not over the counter.

Patients who are uninsured or underinsured and do not qualify for the savings card may apply to the Novartis Patient Assistance Program (PAP), which provides the drug at no cost to qualifying low-income patients who meet federal poverty level thresholds. The PAP application requires income documentation and is reviewed on a case-by-case basis [7].

Is Compounded Inclisiran Legal in West Virginia?

Compounded inclisiran is legal in West Virginia when prepared by a licensed 503A compounding pharmacy that is operating in compliance with state pharmacy board regulations and the federal Drug Quality and Security Act [8]. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. West Virginia has no state-specific law that prohibits compounding inclisiran.

The FDA's classification of inclisiran matters here. Inclisiran is not on the FDA's list of drugs that may not be compounded under section 503A, so compounding is permissible under federal law for individual patient prescriptions [8]. The compound uses the same active moiety (inclisiran sodium) but is formulated by the compounding pharmacist rather than manufactured by Novartis. Quality controls, sterility testing, and beyond-use dating follow USP Chapter 797 standards for sterile compounding.

Cost is the primary driver of interest in compounded inclisiran. Licensed 503A pharmacies offering compounded inclisiran have reported prices that are substantially below the Novartis list price, and some cash-pay patients in West Virginia have obtained the compound at near-zero cost through specific pharmacies. Exact pricing varies by pharmacy, lot size, and the specific siRNA manufacturing pathway used. Any West Virginia patient considering this route should verify the pharmacy's state license on the WV Board of Pharmacy website and confirm USP 797 sterile compounding compliance before proceeding.

The clinical risk to consider: compounded preparations are not FDA-approved, meaning the formulation has not undergone the same analytical testing, pharmacokinetic validation, or bioequivalence studies as Leqvio. A prescriber should document informed consent when prescribing compounded inclisiran and monitor LDL-C response at 90 days to confirm efficacy.

What Do the Clinical Trials Show About Inclisiran's LDL-C Reduction?

The key phase 3 data come from ORION-10 and ORION-11, both published in the New England Journal of Medicine in 2020. ORION-10 enrolled 1,561 patients with ASCVD and elevated LDL-C on maximally tolerated statins. Inclisiran 284 mg subcutaneous injection on day 1, day 90, and then every 180 days reduced LDL-C by 51% from baseline at day 510 versus a 1% change with placebo (P<0.001) [1]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD risk equivalents and replicated the finding, with a 50% LDL-C reduction versus 1% placebo (P<0.001) [1].

The time-averaged LDL-C reduction across the dosing interval was approximately 50% in both trials, which is clinically relevant because cardiovascular risk tracks with average LDL-C exposure over time, not just nadir values [1]. In the pooled analysis, 81% of inclisiran-treated patients achieved LDL-C <70 mg/dL versus 21% on placebo [9].

Safety was favorable. Injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% on placebo, but most were mild. Rates of muscle-related adverse events, liver enzyme elevations, and serious adverse events were similar between arms [1]. The ACC/AHA Pooled Cohort equations predict that a 50% LDL-C reduction in a high-risk patient lowers 10-year ASCVD event risk proportionally, consistent with the Cholesterol Treatment Trialists' meta-analysis of 26 statin trials showing a 22% relative risk reduction per 1 mmol/L LDL-C reduction [10].

The ORION-4 trial (N=15,000, ongoing as of 2026) is the cardiovascular outcomes trial for inclisiran, randomized to inclisiran versus placebo on top of standard care, with primary endpoints of major adverse cardiovascular events [11]. Outcomes data from ORION-4 are expected to provide definitive evidence on whether LDL-C lowering with inclisiran translates to hard event reduction at the same magnitude seen with statins and PCSK9 monoclonal antibodies.

The ACC/AHA guideline states: "For patients with very high-risk ASCVD, a LDL-C threshold of 70 mg/dL is recommended, and if not achieved on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level A)" [6]. Inclisiran, while mechanistically distinct from the monoclonal PCSK9 inhibitors, reduces PCSK9 activity through the same upstream pathway and achieves comparable LDL-C lowering in trial populations.

Can You Get Leqvio via Telehealth in West Virginia?

Telehealth prescribing of Leqvio is permitted in West Virginia under the state's telehealth statute, WV Code §16-2J-1 et seq., which allows licensed West Virginia prescribers to establish a valid patient-prescriber relationship via synchronous audiovisual telemedicine [12]. A prescriber can evaluate a patient's lipid panel, cardiovascular history, and current medications via telehealth, then send an inclisiran prescription to a specialty pharmacy or, for compounded inclisiran, to a licensed 503A pharmacy.

There is one practical constraint. Inclisiran must be injected subcutaneously, and the FDA label specifies that it should be administered by a healthcare professional, not self-injected by the patient [3]. A West Virginia patient receiving a telehealth prescription still needs to present at a clinic, cardiologist's office, or participating retail health clinic for each injection. The telehealth visit handles the prescription and monitoring; the in-person component handles administration.

HealthRX clinicians who are licensed in West Virginia can initiate a telehealth evaluation for patients with established ASCVD or HeFH, order a baseline lipid panel, and generate the inclisiran prescription. Follow-up LDL-C testing at 90 days and 180 days can also be managed through telehealth with at-home or local laboratory draws.

What Is the Cheapest Way to Get Leqvio in West Virginia in 2026?

The lowest-cost pathway depends on insurance status. For commercially insured patients, combining a prior authorization approval with the Novartis $0 savings card produces the minimum out-of-pocket cost [7]. For Medicare Part B patients, the physician-administered billing route avoids Part D cost-sharing and is often the least expensive option. For uninsured or underinsured patients who do not qualify for the Novartis PAP, compounded inclisiran from a licensed West Virginia or out-of-state 503A pharmacy provides the largest cost reduction relative to list price.

Patients should not attempt to obtain inclisiran from international online pharmacies. The FDA has not approved any foreign-manufactured inclisiran for import, and the agency actively intercepts unapproved drug imports at the border [8]. The legal and safety risks are not mitigated by cost savings.

A practical checklist for a WV patient seeking affordable inclisiran:

1. Confirm diagnosis (ASCVD or HeFH) with documented LDL-C on maximally tolerated statin.
2. Contact the commercial insurer or Medicare to verify prior authorization criteria.
3. Submit a PA with the prescriber's support, including lipid panel results and statin history.
4. If approved commercially, enroll in the Novartis savings card program before the first fill.
5. If denied or uninsured, apply for the Novartis PAP or obtain a prescription for compounded inclisiran from a licensed 503A pharmacy.
6. Schedule injections at a clinical site every 6 months after the two loading doses.
7. Recheck fasting LDL-C at 90 days after each injection to confirm a >40% reduction.

West Virginia Cardiovascular Context: Why LDL Management Is Especially Important Here

West Virginia's cardiovascular disease burden is among the highest in the United States. The CDC reports that WV's age-adjusted coronary heart disease mortality rate is 194.2 per 100,000, compared to the national rate of 138.4 per 100,000 [2]. Obesity prevalence in WV was 40.6% in 2022, the second highest in the nation [2]. Rates of diabetes, hypertension, and tobacco use compound lipid-related cardiovascular risk in the state's population.

The 2023 ACC/AHA Joint Committee on Clinical Practice Guidelines identified LDL-C lowering as the single most evidence-based intervention for reducing ASCVD events in high-risk patients [6]. A 50% LDL-C reduction, the magnitude achieved consistently with inclisiran in ORION-10 and ORION-11, corresponds to an approximate 25% relative reduction in major cardiovascular events based on the Cholesterol Treatment Trialists' proportional-risk model [10]. For a state with WV's baseline cardiovascular mortality, the absolute risk reduction from population-level access to effective LDL therapy would be substantial.

Statin therapy remains the foundation of LDL management and is widely covered by WV Medicaid and commercial plans. High-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) reduce LDL-C by 50 to 55% and are generic and inexpensive [6]. Ezetimibe adds another 15 to 20% reduction and costs under $10 per month at most WV pharmacies [13]. Inclisiran occupies the tier above these agents for patients who remain above LDL-C targets despite both.

The WV Department of Health and Human Resources has not published a state cardiovascular prevention initiative that specifically addresses PCSK9 inhibitor access, but the WV Primary Care Association's community health center network has expanded lipid screening programs in rural counties, which increases the number of patients who are identified as candidates for add-on LDL therapy [14].

Inclisiran vs. Evolocumab and Alirocumab: Practical Cost Differences in WV

For West Virginia patients who cannot access inclisiran due to cost or coverage gaps, evolocumab (Repatha) and alirocumab (Praluent) are the alternative PCSK9 inhibitors with FDA approval for ASCVD and HeFH [15]. Both are monoclonal antibodies given by self-injection every 2 to 4 weeks, compared to inclisiran's twice-yearly schedule.

Amgen's Repatha list price is approximately $550 per month. The Amgen patient support program offers $0 co-pay for eligible commercially insured patients [15]. Both evolocumab and alirocumab have demonstrated cardiovascular outcomes benefit in large trials: FOURIER (N=27,564) showed evolocumab reduced the risk of cardiovascular death, MI, or stroke by 15% over a median 2.2 years versus placebo on top of statin therapy (P<0.001) [16], and ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% at 2.8 years (P<0.001) [17].

Inclisiran does not yet have published cardiovascular outcomes data (ORION-4 results pending), which is the main reason some formularies continue to prefer the monoclonal antibodies when clinical evidence of hard endpoint reduction is required for prior authorization approval. A West Virginia prescriber making the case for inclisiran over a monoclonal antibody will need to emphasize the dosing convenience (twice yearly versus biweekly or monthly) as the primary differentiator, particularly for patients with adherence barriers common in rural WV.